CompletedPhase 1ketamine
Ketamine Challenge Study With JNJ-40411813
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT ID
NCT01101659
Target Enrollment
40 participants
Start Date
2010-02
Est. Completion
2010-07
About This Study
The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine. Effects of JNJ-40411813 on ketamine-induced symptoms will be evaluated about 3 hours after a single oral dose when the concentration of JNJ-40411813 in the blood is at its maximum and up to 24 hours after dose administration to assess the duration of a potential JNJ-40411813 effect.
Conditions Studied
Interventions
- •JNJ-40411813
- •normal saline
- •ketamine
- •Placebo
Eligibility
Sex:MALE
Age:18 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Body mass index (BMI) between 18 and 30 kg/m2 * Nonsmokers * Healthy on the basis of a psychiatric examination according to the MINI screen * Healthy on the basis of clinical laboratory tests performed at screening * Healthy on the basis of physical examination, vital signs (including standing blood pressure and heart rate) or 12 lead ECG at Screening Exclusion Criteria: * Having a contra-indication for the use of ketamine * Significant history of or current psychiatric or neurological illness * Positive urine screen for drugs of abuse at Screening or admission * Positive alcohol breath test at Screening or admission * History of alcohol or drug abuse
Study Locations (1)
Neuss, Germany